Identification of Novel Scaffolds with Dual Role as Antiepileptic and Anti-Breast Cancer.

Aromatase inhibitors with an IC50 value ranging from 1.4 to 49.7uM are known to act as antiepileptic drugs besides being potential breast cancer inhibitors. The aim of the present study is to identify novel antiepileptic aromatase inhibitors with higher activity exploiting the ligand-based pharmacophore approach utilizing the experimentally known inhibitors. The resultant Hypo1 consists of four features and was further validated by using three different strategies. Hypo1 was allowed to screen different databases to identify lead molecules and were further subjected to Lipinski' Rule of Five and ADMET to establish their drug-like properties. Consequently, the obtained 68-screened molecules were subjected to molecular docking by GOLD. Furthermore, the compounds with the highest dock scores were assessed for molecular interaction. Later, the MD simulation was applied to evaluate the protein backbone stabilities and binding energies adapting GROMACS 5.0.6 and MM/PBSA which was followed by the density functional theory (DFT), to analyze their orbital energies and further the energy gap between them. Eventually, the number of Hit molecules was culled to three projecting Hit1, Hit2, and Hit3 as the potential lead compounds based on their highest dock scores, hydrogen bond interaction, lowest energy gap and the least binding energies and stable MD results.